SCHEMBL7010688

SCHEMBL7010688

O=c1[nH]c(=S)[nH]cc1Cc1ccco1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PNP P00491 3/20 0.41
KMT2A Q03164 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
TYMP P19971 1/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
ALOX12 P18054 1/20 0.36
APEX1 P27695 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
KDM3B Q7LBC6 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4418633 0.74 ALDH1A1 (0.53) PNPKMT2AHPGDMEN1ALDH1A1
SCHEMBL7108447 0.74 TSHR (0.43) PNPKMT2ATDP1KDM4EMEN1
SCHEMBL17285588 0.73 ALDH1A1 (0.63) PNPKMT2ATDP1TYMPHPGD
SCHEMBL11431767 0.73 KDM4E (0.42) PNPKMT2ATDP1KDM4EMEN1
SCHEMBL11449181 0.71 PNP (0.51) PNPKMT2ATDP1KDM4EMEN1
SCHEMBL6344169 0.69 PNP (0.65) PNP
SCHEMBL9105430 0.69 KMT2A (0.42) KMT2ATDP1KDM3B
SCHEMBL11450005 0.69 KMT2A (0.49) KMT2ATDP1ALDH1A1
SCHEMBL4423230 0.69 DAO (0.51) KMT2ATDP1MEN1MAPT
SCHEMBL7010634 0.69 PNP (0.51) PNPKMT2ATDP1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028955-B1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 2003-07-16 EP disclosed
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them HICKEY DEIRDRE MARY BERNADETTE (GB) 2002-08-29 US disclosed
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 US disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 EP disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them PLA2G7, PLA2G1B, PLA2G4C PNP 24/4885KMT2A 3285/4885TDP1 940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.